Table 2 Adverse events from mTMZ that were tabulated during the study period
From: Phase I study of low-dose metronomic temozolomide for recurrent malignant gliomas
Adverse events | Severity number of patients (%) | |
|---|---|---|
Grade 1 & 2 | Grade 3 & 4 | |
Hematological | ||
Anemia | 1 (11%) | 0 |
Leukopenia | 2 (22%) | 0 |
Lymphopenia | 2 (22%) | 0 |
Neutropenia | 1 (11%) | 0 |
Thrombocytopenia | 1 (11%) | 0 |
Fatigue | 1 (11%) | 0 |
Gastrointestinal | ||
Increased alkaline phosphatase | 0 | 0 |
Increased ALT | 1 (11%) | 1 (11%) |
Increased AST | 1 ( 11%) | 0 |
Infection | ||
Thrush | 1 (11%) | 0 |
Zoster eruption | 1 (11%) | 0 |
Skin | ||
Petechial rash | 1 (11%) | 0 |